ETC-159, an anti-cancer drug that is currently in early phase clinical trials for use in a subset of colorectal and gynecological cancers, could also prevent some tumors from resisting therapies by blocking a key DNA repair mechanism. Researchers from Duke-NUS Medical School and the Agency for Science, Technology and Research (A*STAR) in Singapore have reported their findings in the journal EMBO Molecular Medicine.